U.S. Markets open in 45 mins.

QIAGEN N.V. (QIA.DE)


XETRA - XETRA Delayed Price. Currency in EUR
Add to watchlist
29.27-0.39 (-1.30%)
As of 2:30PM CEST. Market open.

QIAGEN N.V.

Hulsterweg 82
Venlo 5912 PL
Netherlands
31 77 355 6600
http://www.qiagen.com

SectorHealthcare
IndustryMedical Laboratories & Research
Full Time Employees4,600

Key Executives

NameTitlePayExercisedAge
Mr. Peer Michael SchatzCEO, MD & Member of Management BoardN/AN/A52
Dr. Roland SackersCFO, MD & Member of Management BoardN/AN/A49
Mr. Douglas LiuSr. VP of Global OperationsN/AN/AN/A
Mr. John GilardiVP of Corp. Communications & Investor RelationsN/AN/AN/A
Mr. Jean-Pascal ViolaHead of Corp. Bus. Devel. & Intellectual Property & Litigation and Sr. VPN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. It offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, and library preparation for sequencing applications; and assay technology solutions. The company provides Ingenuity Variant Analysis, a cloud-based platform that interprets data from next-generation sequencing (NGS) analysis; QIAGEN Clinical Insight, an evidence-based decision support solution; CLC Genomics Workbench for the analysis and visualization of data from various NGS platforms; and GeneGlobe, a Web-based portal that enables researchers to search and select gene-and pathway-specific solutions from pre-designed and custom PCR assay kits, NGS assay panels, and other products. It also offers instrumentation systems for laboratories. The company’s automation platforms include QIAsymphony, a modular system; GeneReader NGS System, a sample to insight NGS solution for laboratories; Modaplex, a multimodal automation system; QIAcube, a sample processing instrument; EZ1 Advanced XL for automated nucleic acid purification; QIAxcel for nucleic acid separation; QIAscout that enables researchers to select and isolate viable single cells; PyroMark, a detection platform that enables real-time analysis and quantification of genetic mutations and DNA methylation patterns; QIAgility, a benchtop instrument; and ESEQuant instruments that enable optical measurement for point of need molecular testing in healthcare and other applications. It serves molecular diagnostics, applied testing, pharma, and academia customers. QIAGEN N.V. has a partnership with Bristol-Myers Squibb to develop gene expression profiles for immuno-oncology therapies. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

Corporate Governance

QIAGEN N.V.’s ISS Governance QualityScore as of July 1, 2017 is 6. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 7; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.